Literature DB >> 6149569

Taxol: an antimitotic agent with a new mechanism of action.

J J Manfredi, S B Horwitz.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6149569     DOI: 10.1016/0163-7258(84)90025-1

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


× No keyword cloud information.
  66 in total

Review 1.  New cytotoxic drugs and targets in oncology.

Authors:  J H Beijnen
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

2.  Synergistic cytotoxicity of human recombinant tumour necrosis factor alpha combined with microtubule effectors.

Authors:  J Baumgart; B Schlott; J Suehnel; W Vater; W Schulze; D Behnke
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

3.  The long-term effects of taxol on explants of developing chick optic tectum in culture.

Authors:  M M Bird
Journal:  J Anat       Date:  1991-02       Impact factor: 2.610

4.  Different phosphorylation states of the anaphase promoting complex in response to antimitotic drugs: a quantitative proteomic analysis.

Authors:  Judith A J Steen; Hanno Steen; Ann Georgi; Kenneth Parker; Michael Springer; Marc Kirchner; Fred Hamprecht; Marc W Kirschner
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-17       Impact factor: 11.205

5.  A new parenteral emulsion for the administration of taxol.

Authors:  B D Tarr; T G Sambandan; S H Yalkowsky
Journal:  Pharm Res       Date:  1987-04       Impact factor: 4.200

6.  A cytostatic drug (taxol) which does not inhibit monocyte phagocytosis.

Authors:  L Athlin; L Domellöf; B Norberg
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

7.  The CNS penetrating taxane TPI 287 and the AURKA inhibitor alisertib induce synergistic apoptosis in glioblastoma cells.

Authors:  Cory T Zumbar; Aisulu Usubalieva; Paul D King; Xiaohui Li; Caroline S Mifsud; Hailey M Dalton; Muge Sak; Sara Urio; William M Bryant; Joseph P McElroy; George Farmer; Norman L Lehman
Journal:  J Neurooncol       Date:  2018-02-02       Impact factor: 4.130

8.  Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer.

Authors:  Dannah R Miller; Cherng-Chyi Tzeng; Trey Farmer; Evan T Keller; Steve Caplan; Yu-Shuin Chen; Yeh-Long Chen; Ming-Fong Lin
Journal:  Cancer Lett       Date:  2018-08-03       Impact factor: 8.679

9.  Antifungal properties of taxol and various analogues.

Authors:  D H Young; E L Michelotti; C S Swindell; N E Krauss
Journal:  Experientia       Date:  1992-09-15

10.  Proteomic profiling of human keratinocytes undergoing UVB-induced alternative differentiation reveals TRIpartite Motif Protein 29 as a survival factor.

Authors:  Véronique Bertrand-Vallery; Nathalie Belot; Marc Dieu; Edouard Delaive; Noëlle Ninane; Catherine Demazy; Martine Raes; Michel Salmon; Yves Poumay; Florence Debacq-Chainiaux; Olivier Toussaint
Journal:  PLoS One       Date:  2010-05-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.